Inventage Lab, Inc.

389470 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

20,200.00KRW-450.00 (-2.18%)

Price History

Full chart

Market Stats

Previous Close20,650.00

Open20,600.00

Day Range20,050.00 – 22,000.00

52-Week Range22,650.00 – 101,700.00

Volume50.99K

Market Cap375.75B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.90

50-Day Avg27,881.00

200-Day Avg55,487.00

About

Inventage Lab, Inc., a platform technology company, develops medicines using microfluidics-based drug delivery systems. The company was founded in 2015 and is based in Seongnam-si, South Korea.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMs. Juhee Kim
Employees73
Headquarters612, Woolim Lions Valley 3, Seongnam-si, South Korea, 13403, Korea
Websitehttps://www.inventagelab.com

Leadership

Mr. Donghoon KimVP & Director · b. 1970
Ms. Juhee KimChief Executive Officer · b. 1974

Financials

Income Statement

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	3.72B	658.15M	1.78B	2.94B
Growth (%)	-	-82.33%	+170.90%	+64.83%
Cost of Revenue	401.22M	74.38M	28.57M	5.88B
Gross Profit	3.32B	583.77M	1.75B	-2.94B
Gross Margin	89.23%	88.70%	98.40%	-100.11%
Operating Expense	14.22B	16.56B	20.72B	25.44B
Operating Income	-10.90B	-15.98B	-18.96B	-28.38B
Operating Margin	-292.77%	-2427.53%	-1063.62%	-965.74%
EBITDA	-8.07B	-23.50B	-13.21B	-1.93B
EBITDA Margin	-216.66%	-3570.66%	-740.86%	-65.73%
Net Income	-10.60B	-26.99B	-17.00B	-8.46B
Net Income Margin	-284.54%	-4101.51%	-953.29%	-287.82%
R&D	10.96B	12.20B	16.15B	19.45B
R&D as % of Total Revenue	294.27%	1854.42%	905.84%	661.95%
Interest Expense	103.35M	883.08M	2.14B	4.14B
Interest Expense % of Total Revenue	2.78%	134.18%	120.24%	140.74%

Balance Sheet

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	34.86B	45.18B	72.25B	110.64B
Total Liabilities	4.43B	40.77B	39.69B	29.79B
Total Equity	30.43B	4.41B	32.56B	64.46B
Cash	15.78B	18.48B	17.26B	14.47B

Cash Flow

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-5.19B	-11.71B	-13.76B	-20.31B
Capital Expenditure	1.98B	7.14B	4.22B	7.26B
Free Cash Flow	-7.17B	-18.85B	-17.98B	-27.57B
FCF to OCF	138.15%	160.97%	130.66%	135.77%

Earnings

Report Date	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-329.28	-412.15	-671.31	-2410.50	282.55	284.74	-260.96	-1183.00	-562.43	-802.20	323.00	-440.00	84.09	225.11	-176.94
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap375.75B

Enterprise Value244.35B

Trailing P/E0.00

Forward P/E0.00

Price / Sales151.95

Price / Book3.68

Revenue (TTM)2.47B

Gross Profit (TTM)-4.43B

EBITDA-25.67B

Profit Margin-127.01%

Operating Margin-5851.51%

Return on Equity-12.72%

Return on Assets-13.55%

Shares Outstanding13.28M

Shares Float11.51M

Beta0.90

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%